bullish
Jeisys Medical (287410 KS): Solid Q1 Result; New Product Launch and China Expansion to Drive Growth
341 Views29 May 2023 13:40
SUMMARY
- Jeisys Medical (287410 KS) recorded 15% YoY revenue growth in 1Q23, mainly driven by a 25% YoY growth in consumables due to the increasing number of aesthetic procedures globally.
- As of 1Q23, cumulative sales of two major devices of Jeisys, LinearFirm/LinearZ and Potenza reached 3,411 and 2,431 units, respectively. Expanding installed base should further drive consumables revenue growth.
- Jeisys has launched a new device in domestic market and Japan in current quarter. The company aims to accelerate growth momentum through entry in to new market, including China.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Archimed Group Plans to Conduct a Second Tender Offer for Jeisys Medical25 Jul 2024
- Jeisys Medical (287410 KS): Archimed's Delisting Offer11 Jun 2024
- Tender Offer of Jeisys Medical by Archimed Group10 Jun 2024
- Classys (214150 KS): Strong 1Q23 Result Lifted by Overseas Performance and Consumables Sales26 May 2023
- Classys (214150 KS): Record-High Sales and Profit in 2022; Geography Expansion to Accelerate Growth17 Feb 2023
x